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Abstract
Background: Sphingosine-1-phosphate (S1P), a downstream metabolite of ceramide, induces
various bioactivities via two distinct pathways: as an intracellular second messenger or through
receptor activation. The receptor for S1P (S1PR) is the family of Endothelial differentiation,
sphingolipid G-protein-coupled receptor (EDG). We have here attempted to reveal the expression
of EDG/S1PR in human articular chondrocytes (HAC), exploring the implications of S1P in cartilage
degradation.
Methods: Articular cartilage specimens were obtained from patients with rheumatoid arthritis
(RA), osteoarthritis (OA) or traumatic fracture (representing normal chondrocytes) who
underwent joint surgery. Isolated HAC were cultured in vitro by monolayer and stimulated with S1P
in the presence or absence of inhibitors of signaling molecules. Stimulated cells and culture
supernatants were collected and subjected to analyses using reverse transcription-polymerase
chain reaction (RT-PCR), Western blotting, and enzyme-linked immunosorbent assay (ELISA).
Results: All of the tested HAC samples showed positive results in terms of EDG/S1PR expression
in basal condition. When HAC was stimulated with S1P, a significant increase in prostaglandin (PG)
E2 production was observed together with enhanced expression of cyclooxygenase (COX)-2. S1P
stimulated extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase
(MAPK) in HAC, and the PGE2 induction was abrogated by PD98059 and SB203580. Pertussis toxin
inhibited the PGE2 induction from HAC by S1P, suggesting an essential role for Gi protein. S1P also
attenuated the expression of proteoglycan aggrecan, a component of cartilage matrix, in HAC at
transcriptional level.
Conclusion: It was suggested that the S1P-induced PGE2 was at least in part involved in the
aggrecan-suppressing effect of S1P, seeing as COX inhibitors attenuated the effect. Accordingly,
S1P might play an important role in cartilage degradation in arthritides.
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Background
Sphingosine-1-phosphate (S1P) is a bioactive sphingoli-
pid metabolite formed by phosphorylation of sphingo-
sine through activation of sphingosine kinase (reviewed
in [1]). S1P exhibits pleiotropic functions, such as cell
growth, cell differentiation, survival, angiogenesis, cell
migration, and the regulation of immune functions [1,2].
Although S1P is released mainly from platelets, other cell
types, such as erythrocytes or mononuclear cells, can also
produce S1P [3] and high concentrations of S1P can be
found in human sera (i.e. in nanomolar to micromolar
concentrations) [1,4]. S1P functions via two distinct path-
ways: as an intracellular second messenger or through
activation of specific G protein-coupled receptors. The
receptors for S1P are referred to as S1PRs, and these
include the family of endothelial differentiation, lyso-
phosphatidic acid G-protein-coupled receptors (EDG) so
far identified [1], i.e. EDG1/S1P1, EDG5/S1P2, EDG3/
S1P3, EDG6/S1P4, and EDG8/S1P5. Functional redun-
dancy among the EDG receptors has been reported. In
fact, it has been reported that different cells express differ-
ent EDG receptors, and S1P can potentially stimulate
diverse signals in a variety of cell types as well as within
the same cell. This raises the possibility of diverse biolog-
ical outcomes [2]. For example, although S1P in general
has mitogenic potential, it may also have antiproliferative
potential in certain cell types[5,6].
Osteoarthritis (OA) is a degenerative joint disease in
which the aging process and repeated mechanical load on
the joint are thought to play a key role. Recent investiga-
tions, however, have shed light on the inflammatory
aspects of OA pathogenesis, involving various arrays of
inflammatory mediators such as prostaglandins (PG) [7].
For example, PGE2, a representative PG, has been sug-
gested as a possibly catabolic factor in cartilage. In this
context, we and others have identified expressions of
PGE2 synthases in OA chondrocytes [8,9], suggesting a
PG-mediated degenerative process for cartilage in OA.
Although S1P has been reported to induce production of
PGE2 in several cell types via the activation of cyclooxige-
nase (COX)-2 [5,10-12], its role in human chondrocytes
is still not known. Here we have attempted to clarify the
possible role of S1P in cartilage in HAC, focusing on its
potential to induce PGE2 in chondrocytes.
Methods
Cells
HAC were obtained from patients with osteoarthritis (OA;
N = 41, M/F = 8/33, age 55–86 [mean 77.7]), rheumatoid
arthritis (RA; N = 14, M/F = 1/13, age 45–76 [mean 56.8]),
or traumatic fracture (N; N = 11, M/F = 0/11, age 69–92
[mean 79.8]) who underwent arthroplasty of a knee or
hip joint. The diagnosis of OA was made according to the
criteria of Kellgren and Lawrence [13]. RA was classified
according to the criteria of the American College of Rheu-
matology [14]. Cartilage samples obtained from patients
with traumatic fracture were largely normal and no signif-
icant pathological changes were observed. These samples
were therefore designated as "normal". Written informed
consent was obtained from each patient and the study
protocol was approved by our institution's ethical com-
mittee. The study was performed in compliance with the
World Medical Association Declaration of Helsinki
(1964).
After careful removal of synovial tissue, cartilage was
minced, washed and treated with collagenase. Isolated
chondrocytes were then washed and cultured in vitro by
monolayer in DMEM medium supplemented with 10 %
fetal calf serum (FCS) and antibiotics. The attached cells
(P0) were expanded on type I collagen-coated culture
dishes and the cells at subconfluent (P1 cells) were used
in the experiments. The differentiated phenotypes of the
cells used in the experiments were confirmed through
macroscopic observation and by expressions of type II col-
lagen and aggrecan mRNA (data not shown).
Reagents
Sphingosine-1-phosphate (S1P) was purchased from Cay-
man Chemical Co. (Ann Arbor, M, USA). Recombinant
human IL-1 was purchased from R&D Systems, Inc. (Min-
neapolis, MN, USA). All the following inhibitors were
obtained from Calbiochem by Merck Ltd. (Tokyo, Japan):
SB203580, PD98059, SP600125, and LY294002.
Anti-EDG5 antibody of mouse monoclonal IgG was pur-
chased from Oncogene Research Products (San Diego,
CA, USA), and used for western blot. For immunohisto-
chemistry, anti-EDG5, rabbit-polyclonal antibody (Gene-
sis Biotech Inc., Taiwan, R.O.C.) was used.
Anti-COX-2 antibody was purchased from Cayman
Chemical Company. Anti-p38 mitogen-activated protein
kinase (MAPK), anti-phosphorylated p38 MAPK, anti-
ERK, anti-phosphorylated extracellular signal-regulated
kinase (ERK)-1/2, anti-c-Jun N-terminal kinase (JNK1,
JNK2), and anti-phosphorylated JNK and anti-β-actin
antibodies were purchased from Sigma (Saint Louis, MO,
USA). Anti-glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) was purchased from Abcam Ltd. (Cambridge,
UK).
In vitro stimulation of chondrocytes
Chondrocytes were serum-starved in a medium with 0.5
% FCS for 24 h prior to the experiments and either stimu-
lated or not with IL-1 (10 ng/ml) or S1P for indicated peri-
ods. Where specified, cells were pretreated with pertussisBMC Musculoskeletal Disorders 2007, 8:29 http://www.biomedcentral.com/1471-2474/8/29
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toxin from Bordetella pertussis (Sigma) for 18 h, and
SB203580 (10 µM; p38 MAPK inhibitor), PD98059 (50
µM; ERK1/2 inhibitor), SP600125 (10 µM; JNK inhibitor
II), or LY294002 (50 µM; phosphatidylinositol 3-kinase
(PI3K) inhibitor), Meloxicam (10 µM) or Indomethacin
(25 µM) for 1 h before the addition of S1P. Cell viability
was not affected by S1P (up to 50 µM), the vehicle, or any
of the inhibitors during the culture period, as confirmed
by trypan blue exclusion, flow cytometry or a cell viability
assay (CellTiter 96™ Aqueous Non-Radioactive Cell Prolif-
eration Assay; Promega CO., WI, USA)(data not shown).
Stimulated chondrocytes and culture supernatants were
collected and subjected to the following analyses.
Preparation of specimens of cartilage, and 
immunohistochemistry
Articular cartilage sections were prepared as previously
described [15]. Briefly, cartilage slices were fixed in 4 %
paraformaldehyde/0.01 M phosphate-buffered saline.
After decalcification, the sections were embedded in par-
affin and 5 µm sections were prepared.
After deparaffinization, sections were incubated with pro-
teinase K (DAKO, USA) and Block Ace™ (Dainippon Phar-
maceuticals, Osaka, Japan), followed by incubation with
either anti-EDG5 antibody (Genesis Biotech Inc., Taiwan,
R.O.C.) or rabbit immunoglobulin fraction (DakoCyto-
mation, Glostrup, Denmark) for 1.5 h at room tempera-
ture. Samples were then processed and visualized with
DAKO LSAB+kit/HRP (DAKO) in line with the manufac-
turer's instructions.
RT-PCR
Total RNA was isolated from the cultured cells using RNA-
bee™ (Tel-Test, Inc., Friendswood, TX, USA) in accordance
with the manufacturer's instructions. Expression of mRNA
of the EDG receptors was analyzed by reverse transcrip-
tion-polymerase chain reaction (RT-PCR) using the spe-
cific primer sets (Table 1). The PCR conditions were as
follows: initial denaturation at 94°C, 2 min; 35 cycles of
denaturation at 94°C, 1 min; amplification at 58°C, 1
min; extension at 72°C, 1 min; and final extension at
72°C, 5 min.
The size of amplified products was checked by agarose gel
electrophoresis. For semi-quantitive analyses, relative
band intensities against internal control were calculated
using ImageGauge software (FujiFilm, Tokyo, Japan).
Real-time PCR
Quantitative analysis of mRNA expression for aggrecan
gene was performed using the SYBR Premix Ex Taq™ sys-
tem and LightCycler (Roche Diagnostic) according to the
manufacturer's instructions. The sequences of the primers
used for the Real-time PCR were as follows:
GAPDH: 5') GCACCGTCAAGGCTGAGAAC
3') ATGGTGGTGAAGACGCCAGT
aggrecan: 5') ACCCTGGAAGTCGTGGTGAAAG
3') CGTGGCAATGATGGCACTG
Table 1: primer sequences
specificity sense (5'-3) antisense (5'-3) bp Ref. [GenBank accession nos]
EDG1 TCC TTC ACT TTA GTT TCA AAC CCA AGT 160 [GenBank:NM-001400]
CAA CCC CAG CTC TGA TAA CTC TCA
EDG2 ATT TTG TGT GGT TTG GTG CAA GTC 163 [GenBank:NM-057159]
AGC AGT CCA TAG TCT CAT CCA TCA C
EDG3 AAA ATT AGC TGG ATG CGA TAG CAC 156 [GenBank:NM-005226]
TTT GAG ACA GAG GGT CGC TCT GT
EDG4 CTG ACT GGC AGG ACA AGG TCT G 164 [GenBank:NM-004720]
ACC CCC TAA ACC TGA GAT GGC T
EDG5 CCA AGC ATT ATG TGC TGT GC 206 [GenBank:NM-004230]
CAG AAG GAG GAT GCT GAA GG
EDG6 CTA CTC CAA GCG CTA CAT CCT CT 172 [GenBank:NM-003775]
GAT CAT CAG CAC CGT CTT CAG
EDG7 CTC ATC ATG GTT GTG GTG TAC CTG 156 [GenBank:NM-012152]
GCA TAC CAC AAA CGC CCC TAA G
EDG8 AGG ACC TTG TGG GTG ATA TAG AGG AC 156 [GenBank:NM-030760]
CCC CTT CAC CTT CTC TGG TTT TC
COX2 TTC TGA GAT TGT GGG AAA ATT GCT 305 [GenBank:M90100]
AGA TCA TCT CTG GCT GAG TAT CTT
GAPDH CCA CCC ATG GCA AAT TCC ATG GCA 598 [GenBank:NM-002046]
TCT AGA CGG CAG GTC AGG TCC ACC [24]BMC Musculoskeletal Disorders 2007, 8:29 http://www.biomedcentral.com/1471-2474/8/29
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ELISA
Level of PGE2 in the supernatants was quantified using an
EIA kit (Cayman Chemical Co., Ann Arbor, MI, USA).
Aggrecan release into the supernatants was measured
using a Human Aggrecan (Proteoglycan) EASIA™ ELISA
Kit (BioSource International, Inc.; Camarillo, CA, USA).
Western blotting
Whole cell lysates were extracted from the cultured cells
using standard lysis buffer (20 mM Tris-HCl, 250 mM
NaCl, 1% NP-40, 1 mM dithiothreitol, 10 mM NaF, 2 mM
Na3VO4, and 10 mM Na4P2O7) and stored at -30°C prior
to use. Protein concentration was determined using the
Bradford method (Bio-Rad protein assay reagent; BioRad
Laboratories, Hercules, CA). The lysates were mixed with
migration dye and applied to the SDS-polyacrylamide gel
electrophoresis (PAGE) gel. After transfer to a polyvinyli-
dine difluoride membrane, a primary antibody (as noted
in ''Reagents'') was added. The membrane was then
washed and it reacted with the corresponding second anti-
body. Finally, the signals were visualized with the ECL sys-
tem (Amersham Biosciences). Densitometry of the signal
bands was analyzed using ImageJ software [16].
Statistical significance in each experiment was analyzed
using Prism4™ for Macintosh software (GraphPad Soft-
ware Inc., San Diego, CA, USA)
Results and discussion
Human articular chondrocytes express EDG/S1P receptors
This is, to our knowledge, the first study to show the
expression of EDG/S1P receptors in HAC. As shown in the
representative results of RT-PCR in Figure 1, regardless of
the origin of cartilage (from RA, OA or normal joints),
essentially all of the tested HAC samples expressed most
of the tested EDG families at basal level. We also con-
firmed the expression of representative receptor, EDG5, at
the protein level (Fig. 2A), and also by immunohisto-
chemistry using articular cartilage samples (Fig. 2B).
As indicated, each individual showed a different pattern
of EDG/S1PR family expression. Bearing in mind ligand-
receptor redundancy, variations in receptor expression in
HAC may lead to distinct patterns of response to variable
stimuli for each individual.
RT-PCR analyses for the EDG family receptors of S1P in HAC Figure 1
RT-PCR analyses for the EDG family receptors of S1P in HAC. Chondrocyte samples were analyzed for the expression of 
EDG/S1P receptor families. OA: osteoarthritis; RA: rheumatoid arthritis; N: non-arthritic traumatic fracture; numbers and 
alphabets identify each patient.
EDG5
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OA-2SY  OA-3SY   OA-1SY  RA-7HM  RA-8NY  RA-1AK   N-2TM    N-5OT    N-1NM
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EDG7
EDG6
EDG4
160bp
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S1P increases PGE2 production from chondrocytes via EDG 
receptor
To explore the effect of S1P on human chondrocytes, we
cultured HAC with S1P (at 0.1 to 10 µM) in vitro. The
treatment did not induce proliferation, or negatively
impact the viability of the cultured HAC, for up to 48 h
(data not shown). This seems to be in contrast to findings
in rat chondrocytes, where S1P induced cellular prolifera-
tion via ERK MAPK[17], possibly attributable to differ-
ences in response to S1P between the species.
Lipid mediators such as ceramide, sphingosine or S1P
have been demonstrated to induce PGE2 in several cell
types [5,10-12], a possibly catabolic mediator in articular
cartilage [8,9,18]. We here found that S1P significantly
increased prostaglandin E2 (PGE2) production from HAC
(Fig. 3A). The level of PGE2 (basal or induced) showed
considerable variance between samples, but there was a
consistent tendency toward increased PGE2 production
after S1P stimulation (Fig. 3A and data not shown). We
also observed that HAC cultured in medium containing
fatty acid-free BSA instead of 0.5 % FCS showed a similar
increase in PGE2 after S1P stimulation (data not shown).
The S1P-induced PGE2 production was almost completely
abrogated by Meloxicam, a preferential inhibitor of COX-
2 (Fig. 3A); and the induction of COX-2 expression by S1P
was confirmed by Western blot (Fig. 3B). The enhancing
effect of S1P on PGE2 and COX-2 induction was observed
as dose-dependent between concentrations at 0.1 to 10
µM (Fig. 4A), and was increased as time-dependent to
reach the maximum level at 24 h after stimulation (data
not shown).
Another assay showed that the addition of a Gi protein
inhibitor, pertussis toxin (PTX), suppressed the induction
of PGE2 by S1P (Fig. 4B). Thus it was suggested that PGE2
EDG5 expression in HAC Figure 2
EDG5 expression in HAC. A) Western blot: Whole cell lysates from cultured HAC were subjected to immunoblotting. EDG5 
was detected as a distinct band at 45 kD. B) Immunohistochemistry. Specimens of OA cartilage were subjected to analysis of 
EDG5 expression at protein level. The representative images are shown (N = 3).
EDG5
GAPDH 36 kD
45 kD
OA RA N A)
isotype control anti EDG5 Ab
x100
x200
B)BMC Musculoskeletal Disorders 2007, 8:29 http://www.biomedcentral.com/1471-2474/8/29
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induction by S1P depends on COX-2 and signals via G-
protein-coupled receptors (GPCR), i.e. EDG/S1PR, respec-
tively; of particular interest was the role of Gi protein in
the S1P-induced PGE2 production in HAC.
The PGE2 induction by S1P is mediated via p28 and ERK 
MAPKs
As Kim et al. recently reported on the key role of p38 and
ERK MAPKs in S1P-induced proliferation in rat chondro-
cytes[17], we here explored the intracellular signaling
mechanism of S1P-induced PGE2 production in human
chondrocytes. Results (Fig. 5A, B) of the inhibition assays
demonstrated that the S1P-induced PGE2 production in
HAC was abrogated by PD98059 and SB203580, indicat-
ing the dominant role of ERK1/2 and p38 MAPK; the JNK
inhibitor SP600125 and the PI3K inhibitor LY294002 did
not alter the level of PGE2 production significantly (Fig.
5A). S1P-induced activation of p38 and ERK MAPK, but
not of JNK, was also detected by western blotting (Fig.
5B). These findings indicate that p38 and ERK MAPK are
dominantly responding kinases following S1P stimula-
tion in both rat and human cells leading to downstream
phenomenon such as proliferation and prostanoid pro-
duction.
S1P attenuates proteoglycan aggrecan synthesis by HAC
An important function of articular chondrocytes is to syn-
thesize components of the extracellular matrix of carti-
lage, including proteoglycan and type II collagen. To
investigate whether S1P would affect the matrix synthesis
by HAC, we measured secreted aggrecan as well as expres-
sion of aggrecan mRNA in HAC stimulated with S1P.
The results showed that aggrecan secretion was attenuated
in HAC stimulated with S1P (Fig. 6, left). We analyzed the
dose-dependency of the suppressive effect with S1P using
S1P stimulation induces PGE2 production from HAC Figure 3
S1P stimulation induces PGE2 production from HAC. A): OA chondrocytes were stimulated in vitro with S1P (10 µM) with or 
without meloxicam (Mel; 1 µM) for 24 h, and levels of PGE2 in the culture supernatants were subjected to ELISA in triplicate 
(N = 3 each). B) Expressions of COX-2 were analyzed with western blot (representative results are shown). The intensities of 
bands detected with COX-2 analysis were calculated according to their relative ratio against GAPDH (N = 5).
A)
* p<0.05
* p<0.05 vs nonstim
# p<0.05 vs S1P (10)
B) OA-36FM     OA-37TK
NS  IL S1P  NS IL S1P
COX2
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**p<0.01
control IL-1 S1P
0
1
2
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an OA sample and a non-arthritic sample, and both sam-
ples showed a tendency toward dose-dependence (Fig. 6,
right). In the assay using an OA sample, pre-treatment
with PTX helped the level of aggrecan secretion partly
recover (Fig. 7A). In this regard, as it was found that the
chondrocyte samples tested showed differing patterns of
EDG/S1PR expression (see Fig. 1), the specificity of the
EDG/S1PR family in the aggrecan-suppressing effect
might be sample- or patient-dependent. Further assays
using a sufficient number of samples, as well as inhibitors
for each EDG/S1PR receptor, will therefore be needed to
understand the mechanism in more detail.
Since we were unable to detect any significant upregula-
tion of mRNA among representative aggrecanases (i.e.
ADAMTS (a disintegrin and metalloproteinase domain
with thrombospondin motif) -1, 4, and 5; data not
shown), we hypothesized that the suppression of aggre-
can expression would, at least in part, be due to an inhibi-
tion of aggrecan transcription. The results of quantitative
PCR (Fig. 7B) supported this hypothesis; S1P significantly
suppressed the expression of aggrecan mRNA in HAC.
Meloxicam slightly abrogated the suppressing effect of
S1P, while Indomethacin promoted more effective recov-
ery of the aggrecan expression than Meloxicam (Fig. 7B).
As for the implication of lipids in proteoglycan degrada-
tion in cartilage, Sabatini et al reported that ceramide, an
upstream lipid mediator of S1P, might contribute to
chondrocyte apoptosis [19] and also to cartilage degrada-
tion through the induction of aggrecanase activity[20].
Thus, the possible impact of sphingolipids on the aggreca-
Dose-response and involvement of GPCR in the PGE2 production by S1P Figure 4
Dose-response and involvement of GPCR in the PGE2 production by S1P. A) Dose-response: OA chondrocytes were stimu-
lated in vitro with S1P (0.1, 1 or 10 µM) for 24 h. Top: Levels of PGE2 in the culture supernatants were assayed using ELISA in 
triplicate (N = 3 each). Bottom: A representative result of western blot of COX-2 expression is shown. B): PTX inhibition: OA 
chondrocytes were stimulated in vitro with S1P (10 µM) with or without pertussis toxin (PTX, 10 ng/ml) for 24 h, and levels of 
PGE2 were analyzed using ELISA (N = 3 each, in triplicate).
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nases could have importance beyond the regulation of
gene expression. Since the expression of sphingosine
kinase (SPHK), an enzyme essential for converting sphin-
gosine to S1P, was reported to be enhanced in both OA
and RA synovial tissues [21], sphingolipids might also
play an important role in the pathogenesis of OA [17] and
RA[22].
Although a possible suppressing role of COX-2/PGE2 in
aggrecan expression has been suggested, the precise mech-
anism by which the prostanoids might suppress aggrecan
transcription is still unclear. In our results, the nonselec-
tive COX inhibitor indomethacin (blocks COX-1 and
COX-2) was slightly more effective than meloxicam (a
COX-2-preferential inhibitor) (Fig. 7B), implying that the
amount of COX-induced PGE2, and/or a balance between
COX-1 (constitutive) and COX-2 (inducible) activations
might be factors involved in the S1P-mediated signaling
in HAC. Although the direct effect of PGE2 in proteoglycan
degradation might still cause controversy [23], there
would appear to be a synergy between IL-1, S1P and PGE2.
In conclusion, we have here reported, for the first time,
the possible involvement of the S1P in cartilage degrada-
tion. Since S1P has been detected in sera, the findings of
in vitro experiments ought to be at least partly representa-
tive of the physiological bioactivity of S1P in inflamma-
tory or degenerative articular joints in vivo. In fact, a recent
report described how S1P could be detected in synovial
fluid of RA and OA in higher concentrations than in sera
[22]. A possible relationship between chondrocytes and
sphingolipids would provide a novel tool to help us ana-
MAPK-mediated signaling in the S1P-induced PGE2 production by HAC Figure 5
MAPK-mediated signaling in the S1P-induced PGE2 production by HAC. A) Inhibition assays: OA chondrocytes were stimu-
lated in vitro with S1P (10 µM) for 24 h with or without pre-treatment with inhibitor, and levels of PGE2 in the culture superna-
tants were subjected to ELISA in triplicate (N = 5). SB: SB203580 (10 µM; p38 MAPK inhibitor), PD: PD98059 (50 µM; ERK1/2 
inhibitor), SP: SP600125 (10 µM; JNK inhibitor II), LY: LY294002 (50 µM; PI3K inhibitor). B) Western blot: Chondrocytes (N = 
3) were stimulated in vitro with S1P (10 µM) for the indicated time period, and the lysates were analyzed for activations of sig-
naling molecules.
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lyze and possibly reverse the degradative pathway in carti-
lage structure in arthropathy.
Conclusion
Human articular chondrocytes express the EDG/S1PR
receptors for S1P, and respond to S1P stimulation by
inducing a significant increase of PGE2via COX-2 and
MAPK. It has been suggested that S1P-induced PGE2 is
involved in the aggrecan-suppressing effect of S1P. The
sphingolipid mediator S1P may thus play an important
role in cartilage degradation in arthritides such as osteoar-
thritis.
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S1P attenuates aggrecan synthesis in HAC Figure 6
S1P attenuates aggrecan synthesis in HAC. Aggrecan ELISA. Left: OA chondrocytes were stimulated in vitro with S1P (10 µM) 
for 24 h and the supernatants were analyzed for aggrecan secretion. Right: OA chondrocytes (top) and a nonarthritic chondro-
cytes (bottom) were stimulated with S1P at the indicated concentrations.
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Effect of PTX and COX inhibitors in the aggrecan suppression by S1P Figure 7
Effect of PTX and COX inhibitors in the aggrecan suppression by S1P. A) PTX partly abrogate the suppressing effect of S1P. 
The result of an assay on an OA sample is shown. B) Real-time PCR: aggrecan mRNA. OA chondrocytes were stimulated in 
vitro with S1P (10 µM) for 24 h and the mRNA was analyzed for aggrecan expression (N = 3). mel: meloxicam (1 µM), ind: 
indomethacin (25 µM).
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